Immuno-oncology has become a sub-specialty within oncology due to its potential for substantial and long-term clinical advantage. Using a broad range of agents as antibodies, peptides, small molecules, proteins, cytokines or cell therapies, the immunotherapy can activate the immune system to attack the tumor. We substitute various in vivo cancer models that can be subjected for checkpoint inhibitors, immune cells and targeted therapy.
Vivox’s team specializes in:
- Checkpoint inhibitors
- Cell therapy
- Targeted therapy
- Tumor Imaging (IVIS)
Tumor Imaging (IVIS)
Using IVIS Spectrum optical imaging system, Vivox will help you visualize and quantify pathological changes over the course of a disease and predict its efficacy and mechanism of action.
Targeted therapy
Using a broad range of agents, as antibodies, peptides, small molecules, proteins, cytokines or cell therapies, the immunotherapy can activate the immune system to attack the tumor.
Cell therapy
Vivox can assist you in treating your tumor models by systemical or local injection of your cell therapy items such as: CAR-T, NK cells, TILs, etc.
Checkpoint inhibitors
Treatment response depending on the study interests; anti-CTLA-4, anti-PDL-1, and anti-PD-1 antibodies.